MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Core Insights - MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [1][6] - The company announced a presentation at the ASCO GI Symposium, highlighting the potential of its iNKT cell therapies in treating advanced cancers [1][5] Company Overview - MiNK Therapeutics is pioneering the discovery, development, and commercialization of iNKT cell therapies, with a focus on scalable and reproducible manufacturing for off-the-shelf delivery [6] - The company is headquartered in New York, NY, and actively engages with investors through its website and social media channels [6] Clinical Trials and Research - A Phase 2 trial is evaluating the combination of agenT-797 (iNKT cells), botensilimab, balstilimab, ramucirumab, and paclitaxel in patients with advanced gastroesophageal adenocarcinoma who have received prior therapy [8] - Previous Phase I trial data indicated long-term, durable responses and tolerability in patients with PD-1 refractory cancers, particularly in gastric cancer patients who showed significant clinical and immunologic responses [8] - MiNK plans to provide a clinical update from the ongoing Phase II study in the second half of 2025 [8] Presentation Details - The presentation at the ASCO GI Symposium will cover the Phase II study of agenT-797 in combination with other therapies for advanced gastroesophageal adenocarcinoma [5] - The session is scheduled for January 23, 2025, from 11:30 AM to 1:00 PM PST [5]